EUDAMED European Database on Medical Devices has for years been something companies could postpone. Even as MDR and IVDR reshaped regulatory expectations, many organisations treated it as a future requirement—important, but not urgent. That perception changed fundamentally in November 2025, when the notice confirming the functionality of the first four modules was officially published in the Official Journal of the European Union, triggering the transition toward mandatory use.

From 28 May 2026, the use of the first four modules—Actor registration, UDI/Devices, Notified Bodies and Certificates, and Market Surveillance—will become mandatory across the EU. But the real shift is not the date itself. The real shift is that EUDAMED is now an active, continuously used system. Every new device must be registered before it is placed on the market, and device data is no longer managed internally—it is exposed within a central European infrastructure. At the same time, the pressure is still building. Companies are now operating under rolling deadlines. Manufacturers must register devices already on the market by 28 November 2026, while Notified Bodies’ certificate data must be fully aligned by 27 May 2027. This creates a new type of regulatory reality. EUDAMED does not simply introduce new obligations—it reveals whether your organisation can actually manage regulatory data in a structured and consistent way. Many companies are now discovering gaps in their UDI structures, inconsistencies between documentation and product data, and unclear ownership of regulatory information.

For many organisations, this is also where the need for medical device regulatory consulting becomes clear. EUDAMED is not just a technical system—it requires alignment between regulatory strategy, technical documentation, and data governance, which most companies were not originally structured to manage in an integrated way.

The challenge is no longer preparation. The challenge is whether your current setup can function under continuous regulatory visibility without creating delays, corrections, or risks to market access.

How Billev Pharma East supports your EUDAMED readiness in a live environment

Now that EUDAMED is mandatory, companies are no longer asking what the system is—they are asking why it is not working smoothly in practice. The gap between requirements and execution is where most organisations struggle.

At Billev Pharma East, we support companies with EUDAMED readiness for medical devices—including a structured gap assessment and regulatory scoping—but in today’s context, this is about stabilising and structuring an already active process, not just preparing for it.

We start by identifying where your current setup breaks under real EUDAMED use. This includes reviewing your product portfolio, verifying whether your UDI structures are aligned with device registrations, and assessing whether your documentation supports what is being submitted into the system. In many cases, companies have already started entering data—but without full alignment, which creates ongoing corrections and inefficiencies.

From there, we build a practical implementation model that connects regulatory strategy with daily operations. The goal is not theoretical compliance, but a system that works consistently over time, even as new products are introduced and existing data must be maintained.

The key difference is that we do not treat EUDAMED as a one-time project. We integrate it into your regulatory and quality systems as a continuous process.

Because in 2026, the real risk is not missing a deadline. The real risk is operating in a system where every inconsistency becomes visible.

What companies must manage now: ongoing deadlines and operational pressure

With EUDAMED now live, companies are facing a series of overlapping obligations that extend well beyond the initial May 2026 milestone. The system has effectively introduced a phased pressure model that continues into late 2026 and 2027.

From May 2026 onwards, all new MDR and IVDR devices must be registered in EUDAMED before being placed on the market. This makes the database a direct gatekeeper for market access, meaning that incomplete or inconsistent data can delay product launches.

At the same time, companies must address devices that were already on the market before the system became mandatory. These legacy devices must be registered by late November 2026 if they continue to be sold. This is where the largest operational pressure is currently building, as many portfolios were not originally structured for EUDAMED requirements.

The next layer of complexity comes from certificates. Notified Bodies must upload existing certificate data by May 2027, which means manufacturers must ensure that device data and certification data are fully aligned. Any mismatch between these elements can trigger regulatory questions or inconsistencies within the system.

This challenge becomes even more critical when considering the medical device technical file, which serves as the central source of truth for demonstrating compliance, safety, and performance of the device. The data submitted into EUDAMED must accurately reflect what is documented within the technical file, including device description, intended use, classification, and regulatory status. If discrepancies exist between these sources, they do not remain internal—they become immediately visible within a connected regulatory system.

As a result, companies are no longer managing separate regulatory elements, but a fully integrated data environment where documentation, certificates, and database entries must be continuously aligned. This creates a continuous workload rather than a single milestone. Organisations must manage new registrations, legacy data, and certificate alignment simultaneously, while ensuring that their technical documentation and regulatory data remain consistent across all systems.

EUDAMED therefore forces organisations to move from static compliance to ongoing data governance, where accuracy, ownership, and coordination become critical.

What EUDAMED actually is and how it works in practice

EUDAMED european database on medical devices is the central EU system designed to connect all regulatory information related to medical devices into one integrated infrastructure. It links economic operators, devices, certificates, and market surveillance activities, creating a unified view of the entire product lifecycle.

What makes EUDAMED fundamentally different from previous systems is its interconnected structure. Data entered into one module is not isolated—it directly links to other regulatory elements. Device registration connects to certificates, certificates connect to notified bodies, and all of this feeds into regulatory oversight across EU Member States.

The system is being implemented through a modular approach, where each module becomes mandatory after being declared fully functional by the European Commission. This means that EUDAMED is not a one-time rollout, but an evolving system that continues to expand in scope and impact.

In practice, this transforms how regulatory work is performed. Companies can no longer treat documentation, device data, and certification as separate elements. Everything must be aligned, structured, and continuously updated within a single system.

EUDAMED therefore becomes an operational backbone of regulatory compliance, requiring ongoing maintenance rather than periodic submission.

Why EUDAMED is changing regulatory operations permanently

EUDAMED is not just another regulatory requirement—it represents a structural shift in how compliance is monitored and enforced across the EU.

By centralising data and making it interconnected, the system increases transparency and significantly reduces tolerance for inconsistencies. Authorities can now access and cross-check information more efficiently, while discrepancies between documentation and submitted data become immediately visible.

At the same time, the system introduces a new level of accountability. Companies are no longer managing regulatory information internally with limited external visibility. Instead, they operate within a shared environment where data quality directly affects regulatory perception and trust.

This shift moves regulatory from a document-based model to a data-driven one. Success is no longer defined by having complete documentation, but by maintaining consistent, structured, and accurate data across all regulatory touchpoints.

For companies, this creates both pressure and opportunity. Those that adapt can streamline processes, improve efficiency, and reduce risk. Those that do not will face repeated corrections, delays, and increased scrutiny.

EUDAMED is therefore not a temporary change. It is a permanent transformation of regulatory operations.

What truly matters now is control. This means having a clear overview of your product portfolio, ensuring that your data is consistent across systems, and defining ownership of regulatory information. It also means having a structured plan for managing ongoing deadlines—particularly the pressure around legacy devices in late 2026.

This is also where the choice of partner becomes critical. Because the challenge is no longer theoretical—it is operational. In 2026, EUDAMED is already part of your regulatory reality.
The question is whether your organisation is managing it proactively—or constantly reacting to it.

Turning EUDAMED from pressure into control

EUDAMED is no longer something to prepare for—it is something companies must now manage every day.

What separates companies that stay in control from those that struggle is not knowledge of the requirements, but the ability to structure and execute them in a consistent way. EUDAMED has made one thing clear: fragmented data, unclear ownership, and reactive processes are no longer sustainable.

At Billev Pharma East, we work with companies that are already feeling this pressure—and help them turn it into a structured, manageable system. By combining regulatory strategy with hands-on execution, we ensure that your EUDAMED setup is not just compliant, but stable, scalable, and aligned with your broader regulatory operations.

Because at this stage, you don’t need more explanations.
You need a partner who can make EUDAMED work in practice.

Read also:

• How to select a regulatory partner for class II medical devices
• Which firms specialize in combination products: how to choose the right partner for complex combination products
• Medical device regulatory consulting for Small MedTech: budget-friendly support that actually works

Sources: 1 -European Commission. (2025). The EUDAMED four first modules will be mandatory to use as from 28 May 2026, 2 -European Commission. (n.d.). Getting ready for EUDAMED, 3 – European Commission. (2025). EUDAMED modules timeline (November 2025)

Image credits:

In-article images: Pexels

In-article images: Pexels

Hero image: Pexels